Morgan Stanley Reaffirms “Buy” Rating on Ultragenyx Pharmaceutical (RARE) with $55 PT
The analyst’s bullish stance stemmed from Ultragenyx Pharmaceutical Inc.’s (NASDAQ:RARE) strong financial position, alongside its pivotal late-stage pipeline.
Ultragenyx Pharmaceutical Inc. (RARE)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Baker Bros. Advisors Julian Baker And Felix Baker | 2,772,692 | $83,402,575 | 0.6% | |
| 2. | Suvretta Capital Management Aaron Cowen | 2,019,000 | $60,731,520 | -12% | 1.55% |
| 3. | Rock Springs Capital Management Kris Jenner, Gordon Bussard, Graham Mcphail | 1,246,341 | $37,489,937 | -11% | 2.19% |
| 4. | Schonfeld Strategic Advisors Ryan Tolkin (Cio) | 1,144,589 | $34,429,232 | +102% | 0.2% |
| 5. | Vestal Point Capital Ryan Wilder | 750,000 | $22,560,000 | 1.02% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $43.63 | 5,000 | $218,150.00 | 472,479 | 2019-09-11 | Filing | |
| $52.96 | 1,647 | $87,225.12 | 2,559,741 | 2017-08-28 | Filing | |
| $52.40 | 5,853 | $306,697.20 | 2,558,094 | 2017-08-28 | Filing | |
| $21.00 | 175,000 | $3,675,000.00 | 3,260,240 | 2014-01-31 | Filing | |
| $21.00 | 4,500 | $94,500.00 | 84,255 | 2014-01-30 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $31.51 | 7,942 | $250,252.42 | 98,227 | 2025-10-13 | Filing | |
| $29.17 | 64 | $1,866.88 | 50,242 | 2025-09-18 | Filing | |
| $31.17 | 2,450 | $76,366.50 | 73,271 | 2025-09-12 | Filing | |
| $31.39 | 84 | $2,636.76 | 50,306 | 2025-09-05 | Filing | |
| $37.39 | 2,405 | $89,922.95 | 15,344 | 2025-06-20 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 10,132,728 | $304,792,459 | 0% | |
| 2. | 7,283,296 | $219,081,558 | 0.01% | |
| 3. | 6,425,263 | $193,271,911 | 0% | |
| 4. | 4,011,429 | $120,663,796 | 0.01% | |
| 5. | 3,769,853 | $113,397,178 | 0.31% |
News See All
15 Stocks Set to Explode in 2026
While the market figures out whether artificial intelligence is driving the next bubble or the next industrial revolution, a quiet rotation of capital into the next wave of growth leaders outside Big ...
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q3 2025 Earnings Call Transcript
Operator: Good afternoon, and welcome to the Ultragenyx Third Quarter 2025 Financial Results Conference Call.
Bank of America Securities Remains Bullish on Ultragenyx Pharmaceutical (RARE)
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the best biotech stocks with high potential.
14 Biotech Stocks with High Potential
Healthcare was the second worst performer this year, with pharma and biotech companies under pressure.
Assenagon Boosts Ultragenyx Pharmaceutical Inc. (RARE) Stake by 439% Amid Breakthrough Pipeline
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is among the most promising biotech stocks to buy according to hedge funds. According to a recent disclosure with the SEC, Assenagon Asset Management S.A.
7 Most Promising Biotech Stocks to Buy According to Hedge Funds
If there’s one sector that is gaining popularity each day, it’s definitely the biotechnology market.
Cantor Fitzgerald Reiterates a Buy Rating on Ultragenyx Pharmaceutical (RARE)
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the best strong buy stocks to invest in according to Wall Street.
12 Best Strong Buy Stocks to Invest in According to Wall Street
On September 26, Peter Boockvar, chief investment officer at One Point BFG Wealth Partners, appeared on CNBC to talk about the likelihood of the Federal Reserve’s interest rate cuts, new inflation data...
Is Ultragenyx Pharmaceutical (RARE) a Compelling Long-Term Opportunity?
Sands Capital, an investment management company, released its “Sands Capital Select Growth Strategy” Q2 2025 investor letter. A copy of the letter can be downloaded here. U.S.